Precipio, Inc. (PRPO) is a leading diagnostics company based in the United States, dedicated to advancing patient diagnosis through access to the best and most specialized oncologists in the world. Founded in 2012 and publicly listed under the ticker PRPO on NASDAQ, Precipio provides services to patients, clinicians, and hospitals across the globe.
The company is renowned for its specialized pathology services that dramatically maximize the accuracy and speed of cancer diagnoses. Besides pathology diagnostics, it offers a broad range of diagnostic products overseen by top pathology experts. These offerings include a proprietary diagnostic platform, which enables liquid biopsy for hematologic malignancies, reagents, and custom research and development services.
Partnering with some of the world's top cancer institutions like Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio brings the expertise of these institutions to every pathology result produced. Through this, the company ensures that each patient receives the highest quality diagnosis, interpretation, and treatment recommendations.
Precipio's mission is to improve patient care through facilitating better diagnostic accuracy. To achieve this goal, they have developed a sophisticated telepathology platform, branded as "Icepac". This allows a global reach in delivering expert diagnostic accuracy and diagnostic related products directly to the treating physician and the patient.
This revenue-generating platform has the potential to break barriers as it democratizes access to excellence in diagnostics irrespective of where patients are located geographically. Other lines of revenue for Precipio include the development of innovative technologies, and offering pharma services that include clinical trial diagnostic support.
The company has a strong reputation for quality, further reinforced by its accreditation by the College of American Pathologists and certification under the Clinical Laboratory Improvement Amendments (CLIA). Its robust revenue growth is reflective of the significant value it brings to improving cancer diagnostics and treatment.
As Precipio, Inc. continues to vow its commitments towards battling cancer, it remains a vital player in the biomedical sector by not only offering services and products that are life-changing but also creating a significant financial impact in the healthcare industry.